Impact BioMedical, INC. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Impact BioMedical, INC. stock issued during period, value, acquisitions for the quarter ending 2025-12-31 was $0.00.
- Impact BioMedical, INC. stock issued during period, value, acquisitions for the quarter ending 2025-09-30 was $0.00.
- Impact BioMedical, INC. stock issued during period, value, acquisitions for the quarter ending 2025-06-30 was $0.00.
- Impact BioMedical, INC. stock issued during period, value, acquisitions for the quarter ending 2025-03-31 was $820.00K.
- Impact BioMedical, INC. stock issued during period, value, acquisitions for fiscal 2025 was $820.00K.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $820.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | |
| 2025-03-31 | $820.00K 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |